Last reviewed · How we verify

Venlafaxine XR + Mirtazapine

National Institute of Mental Health (NIMH) · FDA-approved active Small molecule

Venlafaxine XR + Mirtazapine is a Antidepressant combination (SNRI + NaSSA) Small molecule drug developed by National Institute of Mental Health (NIMH). It is currently FDA-approved for Major depressive disorder. Also known as: venlafaxine-XR, mirtazapine.

This combination increases serotonin and norepinephrine levels in the brain while also enhancing serotonergic signaling through alpha-2 antagonism, used to treat depression.

This combination increases serotonin and norepinephrine levels in the brain while also enhancing serotonergic signaling through alpha-2 antagonism, used to treat depression. Used for Major depressive disorder.

At a glance

Generic nameVenlafaxine XR + Mirtazapine
Also known asvenlafaxine-XR, mirtazapine
SponsorNational Institute of Mental Health (NIMH)
Drug classAntidepressant combination (SNRI + NaSSA)
TargetSerotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
ModalitySmall molecule
Therapeutic areaPsychiatry / Mental Health
PhaseFDA-approved

Mechanism of action

Venlafaxine XR is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks reuptake of both serotonin and norepinephrine. Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) that antagonizes alpha-2 autoreceptors and heteroreceptors, increasing norepinephrine and serotonin release, while also blocking serotonin 5-HT2 and 5-HT3 receptors. Together, they provide complementary mechanisms for treating major depressive disorder.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Venlafaxine XR + Mirtazapine

What is Venlafaxine XR + Mirtazapine?

Venlafaxine XR + Mirtazapine is a Antidepressant combination (SNRI + NaSSA) drug developed by National Institute of Mental Health (NIMH), indicated for Major depressive disorder.

How does Venlafaxine XR + Mirtazapine work?

This combination increases serotonin and norepinephrine levels in the brain while also enhancing serotonergic signaling through alpha-2 antagonism, used to treat depression.

What is Venlafaxine XR + Mirtazapine used for?

Venlafaxine XR + Mirtazapine is indicated for Major depressive disorder.

Who makes Venlafaxine XR + Mirtazapine?

Venlafaxine XR + Mirtazapine is developed and marketed by National Institute of Mental Health (NIMH) (see full National Institute of Mental Health (NIMH) pipeline at /company/national-institute-of-mental-health-nimh).

Is Venlafaxine XR + Mirtazapine also known as anything else?

Venlafaxine XR + Mirtazapine is also known as venlafaxine-XR, mirtazapine.

What drug class is Venlafaxine XR + Mirtazapine in?

Venlafaxine XR + Mirtazapine belongs to the Antidepressant combination (SNRI + NaSSA) class. See all Antidepressant combination (SNRI + NaSSA) drugs at /class/antidepressant-combination-snri-nassa.

What development phase is Venlafaxine XR + Mirtazapine in?

Venlafaxine XR + Mirtazapine is FDA-approved (marketed).

What are the side effects of Venlafaxine XR + Mirtazapine?

Common side effects of Venlafaxine XR + Mirtazapine include Sedation, Weight gain, Nausea, Dizziness, Dry mouth, Headache.

What does Venlafaxine XR + Mirtazapine target?

Venlafaxine XR + Mirtazapine targets Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors and is a Antidepressant combination (SNRI + NaSSA).

Related